The Latest Breaking News from Intercept Pharmaceuticals

Intercept Pharmaceuticals's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Intercept Pharmaceuticals's (NASDAQ:ICPT) reported sales totaled $88.58 million. Despite a 52.36% increase in earnings, the company posted a loss of $17.28 million.

Benzinga · Jun 1, 2022

First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) dosed first patient in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis (PBC).

Benzinga · May 11, 2022

Analyst Ratings for Intercept Pharmaceuticals

Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings within the last quarter:

Benzinga · May 9, 2022

Looking Into Intercept Pharmaceuticals's Return On Capital Employed

Intercept Pharmaceuticals (NASDAQ:ICPT) brought in sales totaling $92.40 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 898.9%, resulting in a loss of $36.28 million.

Benzinga · Mar 8, 2022

Analyst Ratings For Intercept Pharmaceuticals

Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter:

Benzinga · Mar 3, 2022

Intercept Pharmaceuticals: Q4 Earnings Insights

  Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q4 earnings results on Wednesday, March 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 2, 2022

Earnings Preview For Intercept Pharmaceuticals

Intercept Pharmaceuticals (NASDAQ:ICPT) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement. Analysts estimate that Intercept Pharmaceuticals will report an earnings per share (EPS) of $-1.10.

Benzinga · Mar 1, 2022